Acrivon Therapeutics, Inc. (ACRV) Dividend History

Company News

• Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis

  Acrivon Therapeutics reported positive data from its ongoing Phase 2 study of ACR-368 in endometrial cancer, with a confirmed overall response rate of 62.5% in OncoSignature-positive patients. The company also disclosed the IND clearance and activation of initial clinical sites for its next candidate, ACR-2316, ahead of schedule.

  GlobeNewswire Inc.
• Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up - Zacks Investment Research

  Athira Pharma has dosed the last patient in the phase II/III LIFT-AD study evaluating its pipeline candidate, fosgonimeton, for the treatment of mild-to-moderate Alzheimer's disease. The study is designed to assess the treatment effects of fosgonimeton across multiple aspects of the disease.

  Zacks Investment Research

  Featured Companies: ADPT ATHA RAPT
• AstraZeneca's (AZN) Tagrisso Gets EU Nod for First-Line NSCLC - Zacks Investment Research

  AstraZeneca's lung cancer drug Tagrisso has been approved by the European Commission for use in combination with chemotherapy as a first-line treatment for advanced EGFR-mutated non-small cell lung cancer. The approval was based on positive data from the FLAURA2 study, which showed Tagrisso plus chemotherapy reduced the risk of disease progression or death by 38% compared to Tagrisso monotherapy.

  Zacks Investment Research

  Featured Companies: ALGS
• SpringWorks (SWTX) Completes NDA Submission for Mirdametinib

  SpringWorks (SWTX) completes the submission of a new drug application for its MEK inhibitor, mirdametinib, for treating patients with neurofibromatosis type 1- associated plexiform neurofibromas.

  Zacks Investment Research

  Featured Companies: ALGS RAPT SWTX
• AstraZeneca (AZN) Imfinzi Combo Gets CHMP Nod for Expanded Use

  The CHMP recommends approval of AstraZeneca's (AZN) Imfinzi plus Lynparza for treating primary advanced or recurrent endometrial cancer based on data from the phase III DUO-E study.

  Zacks Investment Research

  Featured Companies: ALGS MRK